Victoria Meucci Villaflor

Title(s)Health Sciences Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Evaluating Clinical Factors Including HPV Clearance on Survival Outcomes in HPV+ Oropharyngeal Carcinoma. Cancers (Basel). 2025 Aug 27; 17(17). Reyes A, Maroongroge S, Afkhami M, Villaflor V, Amini A, Sampath S, Maghami E, Gernon T, Patel K, Li X, Shreenivas A. PMID: 40940899; PMCID: PMC12427374.
      View in: PubMed   Mentions:
    2. Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. J Immunother Cancer. 2025 Aug 24; 13(8). Ferris RL, Leidner RS, Chung CH, Jimeno A, Lee SM, Sukari A, Nieva JJ, Grilley-Olson JE, Redman R, Wong SJ, Villaflor VM, Misleh J, Finckenstein FG, Chou J, Gastman B, Fiaz R, Catlett M, Yi M, Cohen EEW. PMID: 40854613; PMCID: PMC12382571.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    3. Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors. Cancer Med. 2025 Apr; 14(7):e70724. Chae YK, Duan R, Chung LI, Oh Y, Alexiev B, Shin S, Kim S, Helenowski I, Matsangou M, Villaflor V, Mahalingam D. PMID: 40166913; PMCID: PMC11959299.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    4. Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors. Cancer Immunol Immunother. 2024 Sep 13; 73(11):234. Malhotra J, De S, Nguyen K, Lee P, Villaflor V. PMID: 39271499; PMCID: PMC11399531.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    5. Barriers to and enablers of physical activity participation in lung cancer survivors. PM R. 2024 Dec; 16(12):1307-1316. Fram J, Boss K, Villaflor V, Jayabalan P. PMID: 38874321; PMCID: PMC11626541.
      View in: PubMed   Mentions:
    6. BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors. Cancer Gene Ther. 2024 Apr; 31(4):517-526. Conley AP, Roland CL, Bessudo A, Gastman BR, Villaflor VM, Larson C, Reid TR, Caroen S, Oronsky B, Stirn M, Williams J, Burbano E, Coyle A, Barve MA, Wagle N, Abrouk N, Kesari S. PMID: 38146006; PMCID: PMC11016464.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    7. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816. Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, Guo L, Cho H, Li A, Behal A, Mirzapoiazova T, Massarelli E, Koczywas M, Arvanitis LD, Walser T, Villaflor V, Hamilton S, Mambetsariev I, Sattler M, Nasser MW, Jain M, Batra SK, Soldi R, Sharma S, Fakih M, Mohanty SK, Mainan A, Wu X, Chen Y, He Y, Chou TF, Roy S, Orban J, Kulkarni P, Salgia R. PMID: 37831779; PMCID: PMC10575592.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    8. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity. Cancer Res. 2023 10 02; 83(19):3252-3263. Smith AE, Chan S, Wang Z, McCloskey A, Reilly Q, Wang JZ, Patel HV, Koshizuka K, Soifer HS, Kessler L, Dayoub A, Villaflor V, Adkins DR, Bruce JY, Ho AL, Perez CA, Hanna GJ, Gascó Hernández A, Saunders A, Dale S, Gutkind JS, Burrows F, Malik S. PMID: 37339176; PMCID: PMC10543974.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    9. Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block. JCO Precis Oncol. 2023 Sep; 7:e2200445. Liu J, Amini A, Govindarajan A, Abuali T, Mambetsariev I, Massarelli E, Villaflor V, Villalona-Calero M, West H, Williams T, Salgia R. PMID: 37656950.
      View in: PubMed   Mentions: 3     Fields:    
    10. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2023 11; 24(7):651-659. Ebadi M, Ladbury C, Liu J, Rock A, Onyshchenko M, Villaflor V, Villalona-Calero M, Salgia R, Massarelli E, Lee P, Williams T, Amini A. PMID: 37714807.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. Implications of updated staging system for p16+ oropharyngeal squamous cell carcinoma: Is valuable prognostic information being omitted? Head Neck. 2023 08; 45(8):2079-2086. Vo K, Ladbury C, Tam A, Maghami E, Kang R, Villaflor V, Agulnik M, Gernon T, Glaser S, Amini A. PMID: 37345637.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading? Curr Treat Options Oncol. 2023 09; 24(9):1138-1166. Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, Massarelli E, Sampath S, Amini A, Bell D, Villaflor VM. PMID: 37318724; PMCID: PMC10477128.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    13. Building Team Medicine in the Management of CNS Metastases. J Clin Med. 2023 Jun 07; 12(12). Baskaran AB, Buerki RA, Khan OH, Gondi V, Stupp R, Lukas RV, Villaflor VM. PMID: 37373596; PMCID: PMC10299499.
      View in: PubMed   Mentions: 1  
    14. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722. Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE. PMID: 37182801; PMCID: PMC10696593.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    15. Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going? Curr Treat Options Oncol. 2023 07; 24(7):845-866. Juarez-Vignon Whaley JJ, Afkhami M, Sampath S, Amini A, Bell D, Villaflor VM. PMID: 37145382; PMCID: PMC10271909.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    16. Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. ESMO Open. 2023 04; 8(2):101160. Rudin CM, Cervantes A, Dowlati A, Besse B, Ma B, Costa DB, Schmid P, Heist R, Villaflor VM, Spahn J, Li S, Cha E, Riely GJ, Gettinger S. PMID: 36871392; PMCID: PMC10163154.
      View in: PubMed   Mentions: 3  Translation:Humans
    17. Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma. Clin Lung Cancer. 2023 05; 24(3):244-251. Ladbury C, Abuali T, Liu J, Watkins W, Du D, Massarelli E, Villaflor V, Liu A, Salgia R, Williams T, Glaser S, Amini A. PMID: 36759265.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Wolf in sheep's clothing - Oral proliferative verrucous leukoplakia: Progression with longitudinal molecular insights. Ann Diagn Pathol. 2023 Apr; 63:152104. Afkhami M, Maghami E, Gernon TJ, Villaflor V, Bell D. PMID: 36640643.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    19. GITR agonistic stimulation enhances the anti-tumor immune response in a mouse model of ESCC. Carcinogenesis. 2022 10 22; 43(9):908-918. Wiles KN, Tsikretsis LE, Alioto CM, Hermida de Viveiros PA, Villaflor VM, Tétreault MP. PMID: 35880612; PMCID: PMC9587681.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    20. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2022 Oct 08; 14(19). Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Kulkarni P, Villaflor V, Arvanitis L, Hamilton S, Afkhami M, Pillai R, Armstrong B, Erhunmwunsee L, Massarelli E, Sattler M, Amini A, Salgia R. PMID: 36230855; PMCID: PMC9562655.
      View in: PubMed   Mentions: 12  
    21. Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC. Cancers (Basel). 2022 Aug 18; 14(16). Novak J, Salgia R, West H, Villalona-Calero MA, Sampath S, Williams T, Villaflor V, Massarelli E, Pathak R, Koczywas M, Chau B, Amini A. PMID: 36010982; PMCID: PMC9406789.
      View in: PubMed   Mentions: 4  
    22. BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors. Future Oncol. 2022 Sep; 18(29):3245-3254. Kesari S, Bessudo A, Gastman BR, Conley AP, Villaflor VM, Nabell LM, Madere D, Chacon E, Spencer C, Li L, Larson C, Reid T, Caroen S, Oronsky B, Stirn M, Williams J, Barve MA. PMID: 35950603.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    23. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506. Rosenberg AJ, Agrawal N, Pearson AT, Gooi Z, Blair E, Portugal L, Cursio JF, Juloori A, Chin J, Rouse K, Villaflor VM, Seiwert TY, Izumchenko E, Lingen MW, Haraf DJ, Vokes EE. PMID: 35945244; PMCID: PMC9553920.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    24. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. JCO Precis Oncol. 2022 06; 6:e2100289. Gerratana L, Movarek M, Wehbe F, Katam N, Mahalingam D, Donahue J, Shah A, Chae YK, Mulcahy M, Tsarwhas D, Villaflor V, Kalyan A, Hussein M, Patel J, Chandra S, Platanias LC, Gradishar W, Cristofanilli M, Behdad A. PMID: 35772051.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    25. Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report. Cold Spring Harb Mol Case Stud. 2022 04; 8(3). Pharaon RR, Gernon T, Chang S, Vora N, Villaflor VM, Bell D, Afkhami M, Amini A, Sampath S, Kang R, Maghami EG, Massarelli E. PMID: 35483880; PMCID: PMC9059780.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    26. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2022 02 01; 45(2):49-54. Liu J, Bratton E, Yu X, Ladbury C, Wagner J, West H, Massarelli E, Salgia R, Pathak R, Villaflor V, Villalona-Calero M, Amini A. PMID: 34991107.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Heterotopic SMARCB1-deficient high-grade transformed/dedifferentiated acinic cell carcinoma and sine-qua-non radiology- pathology with TNM challenge. Ann Diagn Pathol. 2022 Apr; 57:151900. Maghami E, Afkhami M, Villaflor V, Bell D. PMID: 35077953.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications. Cancers (Basel). 2021 Sep 16; 13(18). Pathak R, Villaflor VM. PMID: 34572868; PMCID: PMC8470834.
      View in: PubMed   Mentions: 9  
    29. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. Mol Cancer Ther. 2021 11; 20(11):2240-2249. Klempner SJ, Bendell JC, Villaflor VM, Tenner LL, Stein SM, Rottman JB, Naik GS, Sirard CA, Kagey MH, Chaney MF, Strickler JH. PMID: 34482288; PMCID: PMC9398109.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    30. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. Oncologist. 2021 12; 26(12):1052-1061. Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. PMID: 34378270; PMCID: PMC8649039.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    31. Reply to Letter to the Editor. Clin Lung Cancer. 2022 05; 23(3):e173. Oh MS, Villaflor VM. PMID: 34538584.
      View in: PubMed   Mentions:    Fields:    
    32. The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer. Front Oncol. 2021; 11:649963. Pharaon RR, Xing Y, Agulnik M, Villaflor VM. PMID: 34336649; PMCID: PMC8322686.
      View in: PubMed   Mentions: 6  
    33. A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy. J Oncol Pharm Pract. 2021 Dec; 27(8):2010-2013. McGee K, Stone NJ, Wadhwani S, Kanwar YS, Villaflor V, Akhter N. PMID: 33789526.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    34. Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report. Oncologist. 2021 07; 26(7):549-553. Lambden JP, Kelsten MF, Schulte BC, Abbinanti S, Hayes JP, Villaflor V, Agulnik M. PMID: 33594725; PMCID: PMC8265341.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    35. Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation. Pulm Circ. 2021 Jan-Mar; 11(1):2045894021992236. Mylvaganam R, Avery R, Goldberg I, Makowski C, Kalhan R, Villaflor V, Cuttica MJ. PMID: 33623668; PMCID: PMC7878999.
      View in: PubMed   Mentions: 7  
    36. Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. Cancers (Basel). 2020 Dec 20; 12(12). Pathak R, Pharaon RR, Mohanty A, Villaflor VM, Salgia R, Massarelli E. PMID: 33419311; PMCID: PMC7767234.
      View in: PubMed   Mentions: 20  
    37. Lung Cancer Survival in Patients With Autoimmune Disease. JAMA Netw Open. 2020 12 01; 3(12):e2029917. Jacob S, Rahbari K, Tegtmeyer K, Zhao J, Tran S, Helenowski I, Zhang H, Walunas T, Varga J, Dematte J, Villaflor V. PMID: 33315114; PMCID: PMC7737093.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    38. Nasopharyngeal Cancer: Is the Addition of Chemotherapy to Radiotherapy Worthwhile in an Era of Value-Based Care? JCO Oncol Pract. 2020 11; 16(11):711-712. Villaflor VM, Massarelli E. PMID: 32946323.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clin Lung Cancer. 2021 01; 22(1):e57-e62. Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, Villaflor VM. PMID: 32900613; PMCID: PMC7785632.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    40. The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. Oncotarget. 2020 May 26; 11(21):1953-1960. Galvez C, Jacob S, Finkelman BS, Zhao J, Tegtmeyer K, Chae YK, Mohindra N, Salgia R, Jovanovic B, Behdad A, Villaflor V. PMID: 32523650; PMCID: PMC7260116.
      View in: PubMed   Mentions: 14     Fields:    
    41. Survivorship support in head and neck cancer: American Head and Neck Society survey. Head Neck. 2020 05; 42(5):939-944. Cognetti DM, Villaflor VM, Fakhry C, Miller MC, Malloy KM. PMID: 31922320.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    42. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 10 01; 30(10):1673. Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. PMID: 31168601.
      View in: PubMed   Mentions: 17     Fields:    
    43. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. J Thorac Oncol. 2019 10; 14(10):1807-1817. Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W. PMID: 31238177.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    44. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Oncologist. 2019 06; 24(6):820-828. Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, Villaflor V, Park W, Lopes G, Giles FJ. PMID: 30867242; PMCID: PMC6656496.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    45. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302. Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. PMID: 30481287.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCellsCTClinical Trials
    46. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2018 Dec 01; 24(23):6099. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. PMID: 30510088.
      View in: PubMed   Mentions:    Fields:    
    47. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019 03; 20(2):88-96.e6. Chae YK, Davis AA, Raparia K, Agte S, Pan A, Mohindra N, Villaflor V, Giles F. PMID: 30425022.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    48. Heuristic value-based framework for lung cancer decision-making. Oncotarget. 2018 Jul 06; 9(52):29877-29891. Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R. PMID: 30042820; PMCID: PMC6057456.
      View in: PubMed   Mentions: 4     Fields:    
    49. Complexity of Delivering Precision Medicine: Opportunities and Challenges. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:998-1007. Davis AA, McKee AE, Kibbe WA, Villaflor VM. PMID: 30231318.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    50. Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. Oncotarget. 2018 May 04; 9(34):23482-23493. Rosenberg AJ, Wainwright DA, Rademaker A, Galvez C, Genet M, Zhai L, Lauing KL, Mulcahy MF, Hayes JP, Odell DD, Horbinski C, Komanduri S, Tetreault MP, Kim KA, Villaflor VM. PMID: 29805749; PMCID: PMC5955099.
      View in: PubMed   Mentions: 18     Fields:    
    51. Immune checkpoint pathways in non-small cell lung cancer. Ann Transl Med. 2018 Mar; 6(5):88. Chae YK, Arya A, Iams W, Cruz M, Mohindra N, Villaflor V, Giles FJ. PMID: 29666811; PMCID: PMC5890048.
      View in: PubMed   Mentions: 11  
    52. Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? Oncotarget. 2017 Nov 21; 8(59):100863-100898. Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V, Cristofanilli M, Giles F. PMID: 29246028; PMCID: PMC5725070.
      View in: PubMed   Mentions: 12     Fields:    
    53. Added diagnostic utility of PET in a patient with subacute encephalopathy and small-cell lung cancer. Lung Cancer Manag. 2017 Jul; 6(1):9-16. Gera A, Kamson DO, Villaflor VM, Lukas RV. PMID: 30643565; PMCID: PMC6310319.
      View in: PubMed   Mentions:
    54. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg. 2017 07; 41(7):1719-1725. Iams WT, Villaflor VM. PMID: 28271259.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    55. Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib. Int J Surg Pathol. 2017 Oct; 25(7):613-618. Cipriani NA, Blair EA, Finkle J, Kraninger JL, Straus CM, Villaflor VM, Ginat DT. PMID: 28497708.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    56. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017 Feb 28; 8(9):16052-16074. Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ. PMID: 28030802; PMCID: PMC5362545.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansCells
    57. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017 Jan 31; 8(5):8910-8920. Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. PMID: 27852042; PMCID: PMC5352453.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    58. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891. Villaflor V, Won B, Nagy R, Banks K, Lanman RB, Talasaz A, Salgia R. PMID: 27602770; PMCID: PMC5341844.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    59. Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer. Clin Lung Cancer. 2017 03; 18(2):132-140. Chae YK, Pan A, Davis AA, Mohindra N, Matsangou M, Villaflor V, Giles F. PMID: 27520630.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    60. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016 08 10; 34(23):2736-42. Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. PMID: 27382098; PMCID: PMC5019745.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    61. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9. Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE. PMID: 27511844.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    62. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86. Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R. PMID: 26934441; PMCID: PMC4951336.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    63. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13. Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ. PMID: 26884588.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    64. Oral Cavity Clear Cell Odontogenic Carcinoma. Head Neck Pathol. 2016 Jun; 10(2):217-20. Ginat DT, Villaflor V, Cipriani NA. PMID: 25994920; PMCID: PMC4838979.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    65. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res. 2015 May; 3(5):567-74. Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen EE. PMID: 25769300; PMCID: PMC4681575.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    66. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. PMID: 25767293; PMCID: PMC5032632.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimalsCells
    67. Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature. Dis Esophagus. 2015 Nov-Dec; 28(8):772-81. Lukas RV, Mata-Machado NA, Nicholas MK, Salgia R, Antic T, Villaflor VM. PMID: 25142531.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    68. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. PMID: 25049329; PMCID: PMC4876357.
      View in: PubMed   Mentions: 192     Fields:    Translation:HumansCTClinical Trials
    69. O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. J Carcinog. 2013; 12:20. Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R. PMID: 24319345; PMCID: PMC3853796.
      View in: PubMed   Mentions: 10  
    70. Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? J Carcinog. 2013; 12:7. Villaflor VM, Salgia R. PMID: 23599689; PMCID: PMC3622362.
      View in: PubMed   Mentions: 6  
    71. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013 Mar 20; 31(9):1134-9. Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB. PMID: 23423747; PMCID: PMC3595423.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    72. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol. 2012 Dec 14; 18(46):6737-46. Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. PMID: 23239911; PMCID: PMC3520162.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    73. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76. Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. PMID: 23104721; PMCID: PMC3662388.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    74. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94. Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R. PMID: 23100466.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    75. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. PMID: 22198429.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    76. Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. J Neurol Res. 2012 Feb 01; 2(1):1-9. Lukas RV, Nicholas MK, Villaflor V, Hoffman PC, Salgia R. PMID: 23504695; PMCID: PMC3596833.
      View in: PubMed   Mentions: 4  
    77. Chemoradiation for patients with large-volume laryngeal cancers. Head Neck. 2012 Aug; 34(8):1162-7. Stenson KM, Maccracken E, Kunnavakkam R, W Cohen EE, Portugal LD, Villaflor V, Seiwert T, Blair E, Haraf DJ, Salama JK, Vokes EE. PMID: 22052816.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    78. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. PMID: 22020702.
      View in: PubMed   Mentions: 134     Fields:    Translation:HumansCTClinical Trials
    79. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31. Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA. PMID: 21791072; PMCID: PMC3189162.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    80. Should esophageal resections for cancer be performed in high-volume centers only? Updates Surg. 2011 Sep; 63(3):147-50. Feo CV, Villaflor VM, Patti MG. PMID: 21695513.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    81. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50. Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK. PMID: 21676484.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    82. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8. Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK. PMID: 21671479.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    83. Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma. J Clin Oncol. 2011 Jul 10; 29(20):e598-600. Schweizer MT, Mehta R, Salgia R, Villaflor VM. PMID: 21519014.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    84. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83. Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. PMID: 21421117.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    85. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507. Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EEW. PMID: 21385883.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    86. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma. 2011 Feb 28; 1(8):1-11. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R. PMID: 21603121; PMCID: PMC3164615.
      View in: PubMed   Mentions: 8  
    87. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol. 2010 Aug 14; 16(30):3793-803. Campbell NP, Villaflor VM. PMID: 20698042; PMCID: PMC2921091.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    88. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009 Jul; 4(7):869-74. Lilenbaum R, Villaflor VM, Langer C, O'Byrne K, O'Brien M, Ross HJ, Socinski M, Oldham FB, Sandilac L, Singer JW, Bonomi P. PMID: 19487960.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    89. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94. Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P. PMID: 18381949.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    90. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007 May; 2(5):414-22. Buckingham LE, Coon JS, Morrison LE, Jacobson KK, Jewell SS, Kaiser KA, Mauer AM, Muzzafar T, Polowy C, Basu S, Gale M, Villaflor VM, Bonomi P. PMID: 17473657.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    91. Other compounds and targets in non-small cell lung cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 10):S30-6. Villaflor V, Bonomi P. PMID: 16459177.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Victoria's Networks
    Concepts (294)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (10)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California